Intuitive Surgical (ISRG) to Release Quarterly Earnings on Tuesday

Intuitive Surgical (NASDAQ:ISRG) will likely be announcing its earnings results after the market closes on Tuesday, April 22nd. Analysts expect Intuitive Surgical to post earnings of $1.71 per share and revenue of $2.19 billion for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Intuitive Surgical Trading Up 0.3 %

Shares of NASDAQ ISRG opened at $482.74 on Friday. The company has a 50-day moving average of $522.23 and a 200 day moving average of $532.34. Intuitive Surgical has a 12-month low of $364.31 and a 12-month high of $616.00. The stock has a market cap of $171.94 billion, a PE ratio of 75.31, a P/E/G ratio of 5.85 and a beta of 1.55.

Insider Buying and Selling at Intuitive Surgical

In related news, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. This trade represents a 27.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jamie Samath sold 269 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $590.00, for a total value of $158,710.00. Following the sale, the chief financial officer now owns 3,282 shares in the company, valued at approximately $1,936,380. This trade represents a 7.58 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,754 shares of company stock valued at $17,691,621 in the last three months. 0.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Intuitive Surgical

An institutional investor recently raised its position in Intuitive Surgical stock. Brighton Jones LLC boosted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 24.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,672 shares of the medical equipment provider’s stock after acquiring an additional 731 shares during the period. Brighton Jones LLC’s holdings in Intuitive Surgical were worth $1,916,000 as of its most recent SEC filing. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on ISRG shares. Erste Group Bank cut Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a report on Monday, March 17th. Piper Sandler reiterated an “overweight” rating and set a $670.00 price target (up previously from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. Royal Bank of Canada boosted their price target on shares of Intuitive Surgical from $611.00 to $641.00 in a research report on Monday, January 27th. Citigroup raised their price objective on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. Finally, Robert W. Baird decreased their target price on shares of Intuitive Surgical from $707.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus target price of $611.81.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.